Learn How to Analyze Your Market and Trading Plan

From RJO Futures | Ad

Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.

Download Your FREE Options Trading Strategy Guide today!

ARCT Insider Trading (Arcturus Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.60%

Insider Buying (Last 12 Months): $195,388.50

Insider Selling (Last 12 Months): $48,572,292.70

Arcturus Therapeutics Insider Trading History Chart

Arcturus Therapeutics Share Price & Price History

^$28.86

▲ +3.07 (11.90%)

As of 05/14/2021 01:00 AM ET

Days: 30 | 90 | 365

Gain the Knowledge You Need to Successfully Trade Futures Markets

From RJO Futures | Ad

Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.

Download Your Complimentary Technical Analysis Guide TODAY!

Arcturus Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/4/2021	Pad Chivukula	COO	Sell	10,000	$46.40	$464,000.00
12/8/2020	Ultragenyx Pharmaceutical Inc.	Director	Sell	442,255	$105.54	$46,675,592.70	2,557,745
11/2/2020	Pad Chivukula	COO	Sell	10,000	$55.28	$552,800.00
10/1/2020	Pad Chivukula	COO	Sell	10,000	$42.83	$428,300.00
9/3/2020	Pad Chivukula	COO	Sell	10,000	$45.16	$451,600.00
6/12/2020	Keith C Kummerfeld	Insider	Buy	450	$33.33	$14,998.50	950
6/10/2020	Andy Sassine	CFO	Buy	5,000	$29.74	$148,700.00	273,245
6/10/2020	Joseph E. Payne	CEO	Buy	1,000	$31.69	$31,690.00
12/5/2019	Andy Sassine	CFO	Buy	5,649	$9.73	$54,964.77	268,245
9/13/2019	Magda Marquet	Director	Buy	2,300	$10.58	$24,334.00
8/29/2019	Joseph E. Payne	CEO	Buy	5,000	$11.22	$56,100.00
8/23/2019	Andy Sassine	CFO	Buy	10,000	$10.90	$109,000.00
8/20/2019	Peter C Farrell	Director	Buy	9,113	$10.94	$99,696.22

SEC Filings (Institutional Ownership Changes) for Arcturus Therapeutics (NASDAQ:ARCT)

74.33% of Arcturus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Arcturus Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/14/2021	UBS Asset Management Americas Inc.	16,225	$0.67M	0.0%	+11.1%	0.062%
5/14/2021	Dynamic Technology Lab Private Ltd	9,520	$0.39M	0.0%	N/A	0.036%
5/14/2021	Credit Suisse AG	14,702	$0.61M	0.0%	-70.3%	0.056%
5/14/2021	Quantbot Technologies LP	1,286	$53K	0.0%	N/A	0.005%
5/13/2021	Trexquant Investment LP	5,428	$0.22M	0.0%	N/A	0.021%
5/13/2021	SG Americas Securities LLC	7,355	$0.30M	0.0%	N/A	0.028%
5/13/2021	ARK Investment Management LLC	3,331,889	$137.61M	0.3%	-15.8%	12.659%
5/13/2021	Barclays PLC	34,131	$1.41M	0.0%	-55.0%	0.130%
5/13/2021	Renaissance Technologies LLC	142,800	$5.90M	0.0%	N/A	0.543%
5/13/2021	Bank of New York Mellon Corp	73,785	$3.05M	0.0%	-9.1%	0.280%
5/13/2021	Citigroup Inc.	83,821	$3.46M	0.0%	+966.6%	0.318%
5/13/2021	Massachusetts Financial Services Co. MA	8,483	$0.35M	0.0%	-36.8%	0.032%
5/13/2021	Federated Hermes Inc.	3,203,000	$132.28M	0.3%	-7.2%	12.169%
5/13/2021	Bank of Montreal Can	927	$35K	0.0%	-94.8%	0.004%
5/13/2021	Platinum Investment Management Ltd.	56,445	$2.33M	0.1%	+27.3%	0.214%
5/13/2021	Allianz Asset Management GmbH	10,508	$0.43M	0.0%	+52.9%	0.040%
5/12/2021	Northern Trust Corp	244,298	$10.09M	0.0%	-14.7%	0.928%
5/12/2021	Ergoteles LLC	5,533	$0.23M	0.0%	N/A	0.021%
5/12/2021	Geode Capital Management LLC	355,896	$14.70M	0.0%	+9.7%	1.352%
5/12/2021	Formidable Asset Management LLC	6,875	$0.28M	0.1%	N/A	0.026%
5/12/2021	JPMorgan Chase & Co.	242,060	$10M	0.0%	+103.7%	0.920%
5/12/2021	Panagora Asset Management Inc.	15,951	$0.66M	0.0%	+140.6%	0.061%
5/12/2021	E Fund Management Co. Ltd.	2,802	$0.12M	0.0%	N/A	0.011%
5/12/2021	UBS Group AG	42,810	$1.77M	0.0%	+52.2%	0.163%
5/11/2021	New York State Common Retirement Fund	18,800	$0.78M	0.0%	-5.5%	0.071%
5/10/2021	State Board of Administration of Florida Retirement System	9,103	$0.38M	0.0%	-3.9%	0.035%
5/10/2021	Principal Financial Group Inc.	5,417	$0.22M	0.0%	-48.9%	0.021%
5/10/2021	Rafferty Asset Management LLC	67,346	$2.78M	0.0%	+665.7%	0.256%
5/10/2021	GSA Capital Partners LLP	5,311	$0.22M	0.0%	-18.4%	0.020%
5/10/2021	Bank Julius Baer & Co. Ltd Zurich	415,541	$17.16M	0.1%	+23.6%	1.579%
5/7/2021	Advisors Asset Management Inc.	6,476	$0.27M	0.0%	+167.8%	0.025%
5/7/2021	BlackRock Inc.	1,752,604	$72.38M	0.0%	-1.6%	6.659%
5/7/2021	American International Group Inc.	11,737	$0.49M	0.0%	-8.3%	0.045%
5/7/2021	BNP Paribas Arbitrage SA	5,093	$0.21M	0.0%	+88.2%	0.019%
5/7/2021	Swiss National Bank	44,800	$1.85M	0.0%	+1.6%	0.170%
5/7/2021	Clarus Group Inc.	130,000	$0.53M	0.2%	N/A	0.494%
5/6/2021	Rhumbline Advisers	21,380	$0.88M	0.0%	-13.9%	0.081%
5/6/2021	Scotia Capital Inc.	10,054	$0.42M	0.0%	N/A	0.038%
5/4/2021	Envestnet Asset Management Inc.	9,768	$0.40M	0.0%	N/A	0.037%
5/4/2021	Commonwealth Equity Services LLC	9,849	$0.41M	0.0%	+11.0%	0.037%
5/4/2021	Victory Capital Management Inc.	4,942	$0.20M	0.0%	N/A	0.019%
5/3/2021	Nikko Asset Management Americas Inc.	315,812	$13.04M	0.1%	+13.7%	1.202%
5/3/2021	The Manufacturers Life Insurance Company	10,997	$0.45M	0.0%	-13.3%	0.042%
5/3/2021	Zurcher Kantonalbank Zurich Cantonalbank	5,160	$0.21M	0.0%	+145.8%	0.020%
4/30/2021	Exane Derivatives	1,652	$68K	0.0%	N/A	0.006%
4/30/2021	Claraphi Advisory Network LLC	6,305	$0.26M	0.1%	-7.9%	0.024%
4/30/2021	Creative Planning	45,237	$1.87M	0.0%	+2.3%	0.172%
4/30/2021	Sumitomo Mitsui Trust Holdings Inc.	315,812	$13.04M	0.0%	+134.6%	1.202%
4/29/2021	We Are One Seven LLC	26,990	$1.11M	0.2%	+13.4%	0.103%
4/28/2021	US Bancorp DE	1,770	$73K	0.0%	+276.6%	0.007%
4/26/2021	Wedbush Securities Inc.	26,063	$1.08M	0.1%	N/A	0.099%
4/16/2021	New England Research & Management Inc.	6,005	$0.25M	0.1%	N/A	0.023%
4/16/2021	Clarus Group Inc.	130,000	$0.53M	0.4%	N/A	0.495%
4/5/2021	Pacer Advisors Inc.	1,578	$65K	0.0%	+26.6%	0.006%
3/12/2021	DekaBank Deutsche Girozentrale	8,100	$0.34M	0.0%	N/A	0.031%
3/2/2021	Norges Bank	22,229	$0.96M	0.0%	N/A	0.091%
3/1/2021	UBS Asset Management Americas Inc.	14,600	$0.63M	0.0%	+2.1%	0.060%
2/24/2021	Bank Julius Baer & Co. Ltd Zurich	336,077	$14.58M	0.1%	+148.5%	1.372%
2/23/2021	Principal Financial Group Inc.	10,610	$0.46M	0.0%	N/A	0.043%
2/19/2021	JPMorgan Chase & Co.	118,853	$5.16M	0.0%	+173.4%	0.485%
2/17/2021	Twinbeech Capital LP	6,883	$0.30M	0.0%	N/A	0.028%
2/17/2021	Voloridge Investment Management LLC	50,151	$2.18M	0.0%	N/A	0.205%
2/17/2021	United Capital Financial Advisers LLC	26,266	$1.14M	0.0%	-7.5%	0.107%
2/17/2021	Cetera Investment Advisers	6,020	$0.26M	0.0%	N/A	0.025%
2/16/2021	Orbimed Advisors LLC	1,280,086	$55.53M	0.5%	+106.9%	5.226%
2/16/2021	Tri Locum Partners LP	26,722	$1.16M	0.4%	N/A	0.109%
2/16/2021	Price T Rowe Associates Inc. MD	1,422,179	$61.69M	0.0%	+102.2%	5.806%
2/16/2021	ETF Managers Group LLC	11,913	$0.56M	0.0%	-12.8%	0.049%
2/16/2021	Schroder Investment Management Group	87,525	$3.80M	0.0%	+44.8%	0.357%
2/16/2021	Engineers Gate Manager LP	10,517	$0.46M	0.0%	N/A	0.043%
2/16/2021	Graham Capital Management L.P.	20,000	$0.87M	0.0%	N/A	0.082%
2/16/2021	ExodusPoint Capital Management LP	23,302	$1.01M	0.0%	-37.1%	0.095%
2/16/2021	Charles Schwab Investment Management Inc.	135,830	$5.89M	0.0%	+16.1%	0.555%
2/13/2021	American International Group Inc.	12,795	$0.56M	0.0%	+33.7%	0.052%
2/12/2021	Capital Impact Advisors LLC	155,000	$6.72M	1.7%	+40.9%	0.633%
2/12/2021	Federated Hermes Inc.	3,452,810	$149.78M	0.3%	+150.8%	14.097%
2/12/2021	LPL Financial LLC	5,383	$0.23M	0.0%	N/A	0.022%
2/12/2021	The Manufacturers Life Insurance Company	12,677	$0.55M	0.0%	+44.4%	0.052%
2/12/2021	Credit Suisse AG	49,531	$2.15M	0.0%	-34.4%	0.202%
2/12/2021	Virtus ETF Advisers LLC	2,743	$0.12M	0.0%	N/A	0.011%
2/11/2021	Nikko Asset Management Americas Inc.	277,686	$12.05M	0.1%	+111.7%	1.134%
2/11/2021	Northern Trust Corp	286,372	$12.42M	0.0%	+17.9%	1.169%
2/11/2021	Barclays PLC	75,806	$3.29M	0.0%	+775.0%	0.310%
2/10/2021	Rhumbline Advisers	24,833	$1.08M	0.0%	+47.3%	0.101%
2/10/2021	Panagora Asset Management Inc.	6,630	$0.29M	0.0%	-48.7%	0.027%
2/9/2021	Wells Fargo & Company MN	141,372	$6.13M	0.0%	+85.9%	0.577%
2/9/2021	Liberty Wealth Management LLC	400	$32K	0.0%	N/A	0.002%
2/9/2021	Seven Eight Capital LP	46,819	$2.03M	0.5%	N/A	0.191%
2/9/2021	Bank of New York Mellon Corp	81,213	$3.52M	0.0%	+29.3%	0.332%
2/9/2021	ProShare Advisors LLC	8,656	$0.38M	0.0%	N/A	0.035%
2/8/2021	Alliancebernstein L.P.	30,100	$1.31M	0.0%	+87.0%	0.123%
2/8/2021	State Board of Administration of Florida Retirement System	9,473	$0.41M	0.0%	+11.9%	0.039%
2/8/2021	New York State Common Retirement Fund	19,900	$0.86M	0.0%	+65.8%	0.081%
2/6/2021	Phoenix Wealth Advisors	845	$37K	0.0%	N/A	0.003%
2/5/2021	BlackRock Inc.	1,781,955	$77.30M	0.0%	+53.3%	7.275%
2/5/2021	Swiss National Bank	44,100	$1.91M	0.0%	+1.8%	0.180%
2/5/2021	Sumitomo Mitsui Trust Holdings Inc.	134,604	$5.84M	0.0%	+2.6%	0.550%
2/5/2021	Claraphi Advisory Network LLC	6,845	$0.30M	0.1%	N/A	0.028%
2/4/2021	Cambridge Investment Research Advisors Inc.	6,363	$0.28M	0.0%	N/A	0.026%
2/4/2021	GSA Capital Partners LLP	6,511	$0.28M	0.0%	N/A	0.027%

Data available starting January 2016

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Today's Range

Now: $28.86

$25.77

$28.97

50 Day Range

MA: $36.98

$25.79

$42.15

52 Week Range

Now: $28.86

$24.87

$129.71

Volume

541,644 shs

Average Volume

1,066,716 shs

Market Capitalization

$759.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.01

Who are the company insiders with the largest holdings of Arcturus Therapeutics?

Arcturus Therapeutics' top insider shareholders include:

Ultragenyx Pharmaceutical Inc (Director)
Andy Sassine (CFO)
Keith C Kummerfeld (Insider)
Joseph E Payne (CEO)
Magda Marquet (Director)
Pad Chivukula (COO)
Peter C Farrell (Director)

Who are the major institutional investors of Arcturus Therapeutics?

Arcturus Therapeutics' top institutional investors include:

ARK Investment Management LLC — 12.66%
Federated Hermes Inc. — 12.17%
BlackRock Inc. — 6.66%
Bank Julius Baer & Co. Ltd Zurich — 1.58%
Geode Capital Management LLC — 1.35%
Sumitomo Mitsui Trust Holdings Inc. — 1.20%

Which major investors are selling Arcturus Therapeutics stock?

Within the last quarter, ARCT stock was sold by these institutional investors:

ARK Investment Management LLC
Federated Hermes Inc.
Northern Trust Corp
Barclays PLC
Credit Suisse AG
BlackRock Inc.
Bank of Montreal Can
Bank of New York Mellon Corp

Within the last year, company insiders that have sold Arcturus Therapeutics company stock include:

Ultragenyx Pharmaceutical Inc (Director)
Andy Sassine (CFO)

Which major investors are buying Arcturus Therapeutics stock?

In the previous quarter, ARCT stock was acquired by institutional investors including:

Sumitomo Mitsui Trust Holdings Inc.
Renaissance Technologies LLC
Clarus Group Inc.
Clarus Group Inc.
JPMorgan Chase & Co.
Bank Julius Baer & Co. Ltd Zurich
Citigroup Inc.
Rafferty Asset Management LLC

During the last year, these company insiders have bought Arcturus Therapeutics stock:

Ultragenyx Pharmaceutical Inc (Director)
Andy Sassine (CFO)
Keith C Kummerfeld (Insider)
Joseph E Payne (CEO)
Magda Marquet (Director)

Learn How to Analyze Your Market and Trading Plan

From RJO Futures | Ad

Download Your FREE Options Trading Strategy Guide today!